Your browser doesn't support javascript.
loading
Respuesta a «Seguridad y efectividad de la dapagliflozina con otro inhibidor del SGLT-2: ¿Qué decisión debemos tomar?» / Response to «Security and effectivity from the dapagliflozin with other inhibitor of the SGLT-2: What decision to take?»
Pallarés Carratalá, V; Escobar Cervantes, C.
Affiliation
  • Pallarés Carratalá, V; Unidad de Vigilancia de la Salud. Medicina Familiar y Comunitaria. Universitat Jaume I. Castellón. España
  • Escobar Cervantes, C; Hospital Universitario La Paz. Servicio de Cardiología. Madrid. España
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.) ; 48(3): 220-222, Abr. 2022.
Article in Spanish | IBECS | ID: ibc-205229
Responsible library: ES1.1
Localization: ES15.1 - BNCS
Subject(s)
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors / Hypoglycemic Agents Limits: Humans Language: Spanish Journal: SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.) Year: 2022 Document type: Article Institution/Affiliation country: Hospital Universitario La Paz/España / Unidad de Vigilancia de la Salud/España
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors / Hypoglycemic Agents Limits: Humans Language: Spanish Journal: SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.) Year: 2022 Document type: Article Institution/Affiliation country: Hospital Universitario La Paz/España / Unidad de Vigilancia de la Salud/España